308nm准分子激光治疗儿童白癜风疗效观察

目的评价308nm准分子激光治疗儿童白癜风的疗效及安全性。方法采用自身对照的方法,用Xt-rac颠峰准分子激光系统治疗85例稳定期儿童白癜风患者(年龄≤12岁)的自身对称或相邻皮损,每周治疗1～3次,共30次,每隔10天及治疗结束3天后评价疗效。结果治疗的皮损痊愈12例,显效45例,好转21例,无效7例,显效率为67.1%,有效率为91.8%;未治疗的皮损仍为色素脱失斑。面颈部疗效优于躯干四肢,躯干四肢优于肢端,面颈部非节段型优于节段型。结论308nm准分子激光治疗稳定期儿童白癜风疗效高、副作用少,其疗效与皮损部位有关。     

308nm准分子激光治疗稳定期白癜风疗效观察

目的 308nm准分子激光治疗稳定期白癜风的疗效.方法 采用Xtrac巅峰准分子激光系统治疗,选择498例稳定期白癜风患者皮损1 697片,每周2次,治疗次数10～30次.结果 治疗的皮损痊愈为549片,显效552片,好转403片,无效193片.有效率为64.88%.头面、颈部优于躯干、四肢,躯干、四肢优于肢端.儿童疗效比成人疗效好.痛程越短疗效越好.结论 308准分子激光治疗稳定期白癜风疗效较好,不良反应少.     

308nm准分子激光治疗白癜风临床研究

目的 探讨308nm准分子激光治疗稳定期白癜风的疗效及不良反应.方法 以自身未治疗皮损作为对照,采用Xtrac颠峰准分子激光系统对75例白癜风患者不同部位的皮损进行为期6周的治疗观察,每周2次,共12次,最后1次治疗结束后3d进行疗效评价并对其相关因素进行分析.结果 治疗的皮损6例痊愈,33例显效,30例好转,6例无效,显效率为52.0%,有效率为92.0%;未治疗的皮损均未出现明显变化.治疗反应的影响因素分析,面颈部优于躯干四肢,躯干四肢优于肢端关节处.结论 308nm准分子激光治疗稳定期白癜风疗效高、不良反应少,其疗效与皮损解剖部位相关.     

308nm准分子激光治疗白癜风的疗效评价及患者生活质量评估

目的评价308 nm准分子激光治疗白癜风的临床疗效及安全性。评估308 nm准分子激光治疗对白癜风患者生活质量的影响。方法采用308 nm准分子激光治疗68例白癜风患者,共162片皮损,每周治疗2次,共12~30次,治疗结束后评价临床疗效及安全性。在治疗前后用中文版皮肤病生活质量指数(Dermatology life quality index,DLQI)量表进行问卷调查,评估308 nm准分子激光治疗对白癜风患者生活质量的影响。结果经308 nm准分子激光治疗,皮损的总有效率为80.86%,平均照射5.21次开始出现色素点,面颈部及躯干部的疗效显著,主要不良反应为瘙痒与干燥。治疗后随着色素恢复,皮损面积明显缩小,DLQI评分显著降低,且与色素恢复情况显著负相关。结论 308nm准分子激光治疗白癜风疗效显著、见效快、不良反应少。其在改善皮损的同时能有效提高白癜风患者的生活质量。     

单频准分子光治疗白癜风的临床研究

目的 研究观察单频准分子光308nm局部照射治疗白癜风的临床疗效,评估其安全性.方法 对77例不同临床类型的白癜风患者的201处皮损进行局部照射,每周1次,随访3-6个月.结果 经过准分子光局部照射平均18次,86.6%皮损有不同程度色素恢复,色素恢复随疗程延长而增加,照射24次总有效率为71.0%,显效率为51.6%.躯干、颈部和头面部疗效优于四肢及手足;泛发型和节段型白癜风疗效尤佳.主要不良反应为局部水疱和疼痛,患者能耐受.结论 准分子光局部照射治疗白癜风疗效显著,且不良反应少.     

308 nm准分子激光治疗白癜风临床疗效观察

目的：观察308nm氯化氙准分子激光治疗白癜风的临床疗效及不良反应。方法：采用Xtrac颠峰准分子激光系统对77例白癜风患者不同部位共292处皮损进行治疗,每周1～2次。并观察疗效,达到3级色素恢复后对相关因素进行分析。结果：经治疗面颈部皮损起效最快,其次为躯干部、四肢,褶皱部最慢;年龄〈18岁患者皮损起效快于年龄〉18岁患者;不同性别、疾病分期、病程、皮肤类型患者的起效快慢差异无统计学意义。结论：308nm准分子激光治疗白癜风疗效好,不良反应少,其疗效与年龄、皮损部位有关。     

308 nm准分子激光治疗白癜风疗效与影响因素分析

目的:评价308 nm准分子激光治疗白癜风的疗效及其影响因素。方法:采用308 nm准分子激光系统治疗103例白癜风患者171处皮损,每周治疗1～2次,共12～50次,治疗结束后评价疗效。结果:皮损的总显效率为59.06%,有效率为83.04%。疗效影响因素分析显示不同部位、年龄、病程以及皮损大小对治疗效果有显著影响。结论:308 nm准分子激光治疗白癜风疗效高、副作用少。     

308nm准分子激光治疗白癜风临床分析

目的 观察308nm准分子激光治疗白癜风的效果.方法 统计接受308nm准分子激光一个疗程治疗后的门诊300例白癜风患者的1 051处皮损,逐个对治疗后皮损的色素恢复情况进行统计,并分部位、分级、分年龄段进行分析和评价.结果 1 051处皮损,色素恢复情况:0级18处,Ⅰ级134处,Ⅱ级317处,Ⅲ级431处,Ⅳ级151处;显效率为55.4％;总有效率为85.5％.按部位:显效率排序为面、颈部,胸腹部、背部,上肢、下肢,手、足部;总有效率排序为面部、颈部、胸腹部、背部,上肢,下肢,手、足部.按皮损分级:显效率、总有效率排序为Ⅰ级,Ⅱ级,Ⅲ级,Ⅳ级.按年龄段:显效率、总有效率排序为青少年,中青年,中老年.结论 308nm准分子光治疗仪治疗白癜风疗效好、不良反应少.疗效与部位、皮损分级程度、年龄有关.     

308nm准分子激光联合吡美莫司软膏治疗白癜风临床观察

目的评价308nm准分子激光联合吡美莫司软膏治疗白癜风的疗效和安全性。方法将150例白癜风患者随机分成3组。治疗组50例,308nm准分子激光(2次/周)联合吡美莫司软膏(2次/d)治疗,疗程12周。对照1组50例,单纯予308nm准分子激光治疗,用法同上。对照2组50例,单纯予吡美莫司软膏治疗,用法同上。结果治疗组有效率88.00%,对照1组为70.00%,对照2组为42.00%。治疗组和对照1组及对照2组比较,有效率差异有统计学意义(P<0.05)。治疗组皮损位于面颈部、躯干和四肢者疗效优于对照组(P<0.05),3组肢端皮损疗效差异无统计学意义(P>0.05)。患者均未出现严重不良反应。结论 308nm准分子激光联合吡美莫司软膏治疗位于面颈部、躯干和四肢的白癜风起效快,疗效好,不良反应少。     

308nm准分子激光治疗白癜风的疗效

目的 探讨308 nm准分子激光治疗白癜风的疗效及其不同年龄、不同部位和不同病程患者疗效的差异,以及疗效与疗程之间的关系.方法 应用临床分组比较的开放性研究方法,选择稳定期白癜风患者360例,≥14岁及<14岁者皮损各180处,给予308nm准分子激光局部照射,每周2次共10周(20次),并随访3个月.结果 ≥14岁组和<14岁组治疗总有效率分别为62.2%和63.3%,显效率分别为34.4%和44.4%,两组比较差异无统计学意义(P>0.05);不同部位皮损的疗效显示,面颈部疗效最好,躯干四肢部疗效次之,肢端关节部疗效最差,差异有统计学意义(P均<0.05);不同病程的皮损疗效亦不相同,病程越短疗效越好,适当延长疗程可提高疗效.结论 308 nm准分子激光治疗稳定期白癜风疗效好,起效快,不良反应少,患者的年龄差别对疗效的影响不明显,而皮损的部位、病程和治疗次数对疗效有一定的影响.     

The 308-nm excimer laser: a promising device for the treatment of childhood vitiligo

Background: Numerous modalities have been used to treat vitiligo in children. Up to now, phototherapy and topical corticosteroids are the most commonly used treatments for adult vitiligo but studies evaluating the efficacy of these treatments in the pediatric population remain insufficient. Objective: This study was a retrospective review to evaluate the efficacy and safety of 308‐nm excimer laser treatment in 30 childhood vitiligo patients. Methods: Thirty vitiligo patients with 40 vitiligo patches were evaluated after the cessation of 308‐nm excimer laser treatment. Results: Seventeen patients (56.7%) with 20 patches (50%) achieved an acceptable degree (>50%) of repigmentation at the end of the treatment, with five patches (12.5%) showing >75% of repigmentation. The treatment response showed anatomical preferences, favoring the face, neck and trunk. However, the treatment response did not correlate to the cumulative dose or duration of treatment. Side effects occurred in nine patients, but were transient and minimal. Conclusion: The results of this study shows that the 308‐nm excimer laser can be an effective and promising device for the treatment of various vitiligo types, other than generalized, in childhood.     

Clinical efficacy of a 308 nm excimer laser in the treatment of vitiligo

Objective: To investigate the clinical efficacy and safety of the treatment of vitiligo using a 308 nm excimer laser. Method: Thirty‐six patients with 44 vitiligo patches were treated using a 308 nm excimer laser, which was performed twice a week, for a total of 30 treatments. The therapeutic efficacy and safety were then evaluated. Results: After 30 treatments:
(1) 27/44 patches (61.4%) achieved more than 75% repigmentation, 4/44 lesions (9.1%) showed 51–75% repigmentation, 10/44 (22.7%) showed 26–50% repigmentation and 3/44 (6.8%) showed 1–25% repigmentation.
(2) Of the 44 patches of vitiligo, 20/27 (74.1%) lesions on the face/neck, 9/9 (100%) on the trunk and 2/8 (25.0%) on the extremities showed ≥50% repigmentation. The repigmentation (≥50%) in face/neck and trunk were much higher than that in the extremities (P<0.05).
(3) The repigmentation (≥50%) in disease duration of ≤2 years and >2 years were 100.0% and 46.2% (P<0.05).
(4) The average cumulative doses in the face/neck, trunk and extremities were 7.92±5.26, 9.93±7.36 and 22.13±8.15 J/cm². The doses in the face/neck and trunk were much lower than those in the extremities. (P<0.05). Side effects were limited mainly to symptomatic erythema. Conclusion: The clinical data indicate that the treatment of vitiligo using a 308 nm excimer laser is safe and effective. However, lesion location and disease duration may be the key factors affecting the clinical outcome.     

Treatment of vitiligo with the 308 nm excimer laser

Several therapeutic modalities have been proposed for the treatment of vitiligo either to achive repigmentation in the lesions or to stabilize the disease. Narrow-band UVB therapy has been shown to be effective and safe for use in the management of vitiligo; its wavelength is not so different from 308 nm XeCl excimer laser radiation. We present an open and uncontrolled pilot study of 24 patients (12 men, 12 women) in whom vitiligous patches were treated twice a week, for 9 months with 308 nm XeCl laser radiation. Seven of the 24 patients showed greater than 75% repigmentation, six patients showed repigmentation of between 25 and 75% and six patients showed less than 25% repigmentation. In five patients no signs of repigmentation were noted. The therapeutic benefit was stable during the 12-month follow-up period. Although these results are promising, treatment has so far been limited to small numbers of patients and a short follow-up period. Other prospective studies are needed to assess the efficacy of this treatment modality.     

CO2点阵激光联合308 nm准分子激光治疗白癜风疗效和安全性meta分析

目的：评价CO₂点阵激光联合308 nm准分子激光治疗白癜风的临床疗效和安全性。方法：通过检索Cochrane Library、PubMed、Embase、万方、中国知网、维普数据库,收集CO₂点阵激光与308 nm准分子激光联合治疗白癜风相关的文献,运用软件（Revman 5.3）进行Meta分析。结果：13篇临床随机对照实验被纳入,其中1014处皮损给予CO₂点阵激光与308 nm准分子激光联合治疗,1005处皮损给予308 nm准分子激光单独治疗。结果显示：联合疗法总有效率和显效率优于单用308 nm准分子激光;两组不良反应发生率无明显差异。结论： CO₂点阵激光+308 nm准分子激光联合治疗白癜风的疗效优于单独使用308 nm准分子激光,且两种疗法的不良反应没有明显差异。     

中波高能紫外线与308 nm准分子激光治疗白癜风的短期疗效比较

【摘要】 目的 比较中波高能紫外线和308 nm准分子激光治疗白癜风的短期疗效。 方法 中波高能紫外线组患者40例,每周照射2次;308 nm准分子激光组40例,每周1次。评估两组治疗8周后的皮损复色情况。 结果 经过8周的阶段治疗,中波高能紫外线组有83.6%皮损可出现不同程度的复色反应,达显效以上复色为42.1%;308 nm准分子激光组86.1%有皮损不同程度色素生成,达到显效以上为50%。对于面部白癜风皮损中波高能紫外线的疗效低于308 nm准分子激光（χ2 = 4.32,P < 0. 05）,在其余部位两组有效率差异无统计学意义。在皮损起始复色的累积剂量方面,两者差异无统计学意义（t = 0.89,P > 0.05）,在达到显效以上复色方面,高能中波紫外线的治疗次数和累积剂量明显多于308 nm准分子激光（P < 0. 01）。两者均适用于儿童患者及活动期皮损。 结论 中波高能紫外线或308 nm准分子激光治疗白癜风均可在短期内起效且安全,308 nm准分子激光疗效更明显。     

The efficacy of excimer laser (308 nm) for vitiligo at different body sites

BACKGROUND: The treatment with XeCl-excimer laser generated 308-nm UVB radiation has shown promising results in patients with vitiligo. OBJECTIVE: In this controlled, prospective trial we studied the primary efficacy (start and grade of repigmentation) and patient's satisfaction of XeCl-excimer laser for treatment of vitiligo patches at different body sites and re-evaluated the achieved repigmentation 12 months after the end of therapy. METHODS: Twenty-five patients with generalized or localized vitiligo with a total of 85 lesions at different body sites were enrolled in this study. Vitiligo patches were treated with 308-nm XeCl-excimer laser 3 times a week for 6 to 10 weeks. The overall repigmentation grade of each treated lesion was evaluated once a week on a 5 point scale rating from 0 (no repigmentation), 1 (1-5%), 2 (6-25%), 3 (26-50%), 4 (51-75%), to 5 (76-100%). RESULTS: Twenty-four patients completed the study. Within 6 to 10 weeks of treatment 67% of the patients (16/24) developed follicular repigmentation of at least one of their vitiligo lesions. Lesion repigmentation started after a mean of 13 treatments in lesions located on the face, trunk, arm, and/or leg (high-responder location), and after a mean of 22 treatments in lesions located on the elbow, wrist, dorsum of the hand, knee, and/or dorsum of the foot (low-responder location). Untreated control lesions and lesions located on the fingers did not achieve any repigmentation. After 10 weeks of treatment repigmentation of more than 75% was found in 25% (7/28) of lesions of the high-responder location group versus 2% (1/43) of lesions of the low-responder location group. In most cases, laser-induced repigmentation was persistent, as determined 12 months after the end of treatment. CONCLUSIONS: 308-nm excimer laser is an effective modality for the treatment of vitiligo. However, similar to other non-surgical treatment modalities, the therapeutic effect is mainly dependent on the location of vitiligo lesions.     

Monochromatic excimer light 308 nm in the treatment of vitiligo: a pilot study

OBJECTIVE: To study the efficacy and safety of monochromatic excimer light (MEL) on 37 vitiligo patients referred to our clinic. METHODS: In a pilot study, 37 patients (17 males, 20 females) with acrofacial (n=21), focal (n=11), segmental (n=1), and generalized (n=4) vitiligo were treated twice weekly with MEL for a maximum period of 6 months. RESULTS: Thirty-five patients (95%) showed signs of repigmentation within the first eight treatments. The treatment resulted in good repigmentation in 16 patients, and excellent repigmentation in 18 patients. Adverse events were limited to transient erythema. In addition, some patients (n=3) not responding to prior narrow-band UVB (NB UVB) phototherapy showed good results with MEL in our series. CONCLUSIONS: Treatment with 308 nm MEL for vitiligo may be more effective in obtaining rapid repigmentation than phototherapy with NB UVB. The results in this study are similar to those recently reported with a 308 nm excimer laser, but 308 MEL could present some advantages: the possibility of treating larger areas compared to the 308 nm excimer laser, with shorter treatment times and better patient compliance. The overall good results and the early appearance of repigmentation contribute to reducing the cumulative exposure to UV radiation.     

Treatment of Vitiligo with 308-nm xenon-chloride excimer laser: therapeutic efficacy of different initial doses according to treatment areas

Many preliminary data suggest that the 308-nm excimer laser can be a highly effective therapeutic alternative for treating vitiligo, inducing rapid repigmentation with minimal ultraviolet irradiation. We evaluated the clinical efficacy of the 308-nm excimer laser treatment for various body areas, using different initial UV doses. One hundred forty vitiligo patches from 69 patients were assigned to 4 groups; face and neck, trunk, extremities, and acral and joint areas. They were then treated twice a week, using different initial UV doses. The rate of repigmentation continued to increase with the number of treatments up to 20 sessions, and then showed plateaus between 20 to 30 sessions. On the other hand, the lesions in acral and joint areas showed the worst responses throughout the treatment sessions. Our findings extend previous observations that the 308-nm excimer laser is an effective treatment option for patients with vitiligo. However, further studies will be needed to determine the optimal dosing and administration method, especially for acral and joint areas.     

308‐nm excimer lamp vs. 308‐nm excimer laser for treating vitiligo: a randomized study

Background The 308‐nm excimer laser and 308‐nm excimer lamp have both been shown to be effective in treating vitiligo but a direct comparison has never been performed. Objectives To test the equivalence of these two devices for treating nonsegmental vitiligo. Patients and methods A randomized monocentric study was undertaken. One lesion was treated with the 308‐nm excimer laser and its counterpart with the 308‐nm excimer lamp. Lesions were treated twice weekly with the same dose on both sides for a total of 24 sessions. The evaluation was done by two independent physicians blinded to the treatment on direct light and ultraviolet light photos. Results Twenty patients were included: 17 completed the study and 104 lesions were treated. The two treatments showed similar results in terms of efficacy for a repigmentation of at least 50% (P = 0·006). The lamp induced more erythema than the laser. Conclusions The 308‐nm excimer lamp and laser showed a similar efficacy in treating vitiligo. For the same fluence, the lamp induced more erythema suggesting photobiological differences between the two devices.